)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
AstraZeneca (AZN) investor relations material
AstraZeneca European Society of Cardiology Congress 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.European Society of Cardiology Congress 2025 summary31 Aug, 2025
Strategic ambitions and growth outlook
Reaffirmed $80B/€80B total revenue ambition by 2030, driven by a diverse portfolio, new launches, and not dependent on future M&A.
Focus on expanding in cardiometabolic, oncology, and rare diseases, leveraging global reach and partnerships.
Emphasized innovative therapies targeting overlapping risk factors in cardiorenal and cardiometabolic diseases, including combination approaches and novel mechanisms.
Pipeline includes advanced modalities for weight management, risk factor modification, and multi-organ diseases.
Large patient populations remain uncontrolled or at risk despite current therapies, highlighting need for novel mechanisms.
Addressing unmet needs in cardiometabolic diseases
Cardiometabolic diseases are leading causes of death, with high prevalence of multi-morbidity in older adults.
Ambition to transform care by targeting dyslipidemia, hypertension, heart failure, kidney disease, and weight-related comorbidities.
Innovative combinations and new molecular entities are in development to address multi-risk factor diseases.
Bexarostat/Baxdrostat Phase III trial results and clinical insights
Bexarostat/Baxdrostat, a selective aldosterone synthase inhibitor, showed significant placebo-adjusted reductions in systolic BP (8.7 and 9.8 mmHg for 1mg and 2mg) in patients with uncontrolled or resistant hypertension.
Efficacy was consistent across all pre-specified subgroups, with robust 24-hour and nighttime BP control and sustained effects up to 32 weeks.
Reduced plasma aldosterone by 60–65% and demonstrated positive Phase II data for laroprostat (oral PCSK9 inhibitor) in dyslipidemia.
Safety profile was favorable, with low rates of significant hyperkalemia (1%), minimal discontinuations, and no adrenal insufficiency or relevant drug-drug interactions.
Ongoing Phase III trials in chronic kidney disease, heart failure prevention, and primary aldosteronism aim to expand indications.
Baxdrostat: How will AZN maximize global reach?
Baxdrostat: Address hyperkalaemia management.
Beyond 2030: What are key platform investments?
Bexostat's 24-hr control vs. lorundostat?
Payer strategy for Bexostat market access?
Bexostat's potential beyond hypertension?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next AstraZeneca earnings date
Q3 20256 Nov, 2025
Next AstraZeneca earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Anglo-Swedish Pharmaceuticals
AstraZeneca is a multinational biopharmaceutical company established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Headquartered in Cambridge, UK, the firm operates globally, specializing in the research, development, manufacturing, and commercialization of prescription medications. It focuses on a range of therapeutic areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. AstraZeneca's products cater to a diverse set of medical needs and are distributed in numerous countries worldwide. The company is a major player in the global pharmaceutical industry, maintaining a strong commitment to scientific research and the development of new medicines.
A Successful Merger
As previously mentioned, AstraZeneca came to be following the merger of two established pharmaceutical companies. Astra AB, with roots dating back to 1913, had a notable history in pharmaceutical production, introducing various medicines to the market over the decades. Zeneca on the other hand traces its roots back to 1993 after separating from Imperial Chemical Industries. The British half of the modern-day company had a footprint in both therapeutic products and agrochemicals, although it eventually divested from the latter. The merger of these two entities aimed to consolidate resources, streamline research and development processes, and enhance their presence in the global pharmaceutical market. The combined company, now known as AstraZeneca, has since played a significant role in the industry, building upon the foundational knowledge and experience of the two merged parties.
Research and Development
AstraZeneca primarily focuses on the discovery, development, and commercialization of prescription medicines. Their core areas of activity encompass a range of medical conditions, including respiratory, cardiovascular, renal, metabolic, oncology, and autoimmune diseases. The company also engages in significant research and development efforts, with research centers in the UK, Sweden, and the USA. This focus AstraZeneca was one of the pharmaceutical companies heavily involved with the global effort of finding a suitable vaccine during the Covid-19 pandemic. This is an effort they succeeded in, and together with companies like Pfizer and Moderna, they were a key player in the global vaccination effort.
Serving Patients Worldwide
As is common with large pharmaceutical companies, AstraZeneca has a presence in all corners of the world and the company operates in over 100 countries. It has manufacturing and commercial operations distributed across major markets including North America, Europe, Asia, and emerging economies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage